Navigation

Hannah Yejin Kim

  • UNIVERSITY OF SYDNEY

Author Archive | Hannah Yejin Kim

Saliva for TDM of antifungal drugs: voriconazole model

January 18, 2021

Authors Hannah Yejin Kim (1,2), Anne-Grete Märtson (3), Erwin Dreesen (4), Isabel Spriet (4,5), Sebastian G Wicha (6), Andrew J McLachlan (1), Jan-Willem Alffenaar (1,2)
Affiliations 1. The University of Sydney, 2. Westmead Hospital, 3. University of Groningen, 4. KU Leuven, 5.University Hospitals Leuven, 6. University of Hamburg
Presentation type Oral
Presenters Hannah Yejin Kim

Aims. Therapeutic drug monitoring (TDM) is recommended for many antifungal drugs. Saliva sampling is a non-invasive alternative to plasma sampling. However, no clinically validated saliva models available. This study firstly aims to conduct a systematic review to evaluate the evidence supporting saliva-based TDM for azoles, echinocandins, amphotericin B, and flucytosine. The second aim is to […]

Continue Reading

Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma

January 24, 2018

Authors Hannah Y Kim (1), Xiaoman Liu (1), Janna K Duong (1), Georgina V Long (2), Maria Gonzalez (2), Alexander M Menzies (2), Alan V Boddy (1)
Affiliations 1. Faculty of Pharmacy, University of Sydney, Sydney, NSW, Australia, 2. Melanoma Institute Australia and School of Medicine, University of Sydney, Sydney, NSW, Australia.
Presentation type Oral
Presenters HANNAH YEJIN KIM

Introduction. The combination of a BRAF inhibitor, dabrafenib and a MEK inhibitor, trametinib (CombiDT) has improved survival outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma. However, the use of CombiDT has a high incidence of pyrexia, causing treatment delays (Menzies, 2015). The pharmacokinetics and metabolism of dabrafenib and trametinib may […]

Continue Reading